5,856 Shares in AbbVie Inc. $ABBV Acquired by Clear Trail Advisors LLC

Clear Trail Advisors LLC bought a new position in AbbVie Inc. (NYSE:ABBV) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 5,856 shares of the company’s stock, valued at approximately $1,338,000.

Several other large investors have also recently bought and sold shares of ABBV. Evolution Wealth Management Inc. bought a new stake in AbbVie during the second quarter valued at $26,000. Chelsea Counsel Co. purchased a new position in AbbVie during the third quarter worth about $26,000. Texas Capital Bancshares Inc TX purchased a new position in AbbVie during the third quarter worth about $31,000. Caitlin John LLC bought a new position in AbbVie in the 3rd quarter worth about $33,000. Finally, Delos Wealth Advisors LLC bought a new position in AbbVie in the 2nd quarter worth about $39,000. 70.23% of the stock is owned by institutional investors.

AbbVie Trading Down 0.1%

Shares of NYSE ABBV opened at $204.89 on Tuesday. The stock has a market cap of $362.29 billion, a price-to-earnings ratio of 86.82, a P/E/G ratio of 0.71 and a beta of 0.34. The stock’s 50-day moving average is $222.79 and its 200 day moving average is $224.80. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s revenue was up 10.0% compared to the same quarter last year. During the same period last year, the firm posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Insider Activity

In other news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.08% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ABBV. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Royal Bank Of Canada assumed coverage on shares of AbbVie in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective on the stock. Guggenheim reiterated a “buy” rating on shares of AbbVie in a research report on Thursday, March 12th. Citigroup decreased their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Finally, William Blair restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.